-+ 0.00%
-+ 0.00%
-+ 0.00%

BioVie Trial Data Suggest Bezisterim Improves Cognition in High-Inflammation Long COVID Subgroup

PUBT·11/09/2026 13:02:14
Listen to the news
BioVie Trial Data Suggest Bezisterim Improves Cognition in High-Inflammation Long COVID Subgroup
  • BioVie presented Phase 2 ADDRESS-LC findings for bezisterim in Long COVID at the RECOVER-TLC workshop held November 4-5, 2026.
  • Exploratory analyses linked high inflammation to cognitive improvements; patients with low myeloid cell levels showed improvements in fatigue and post-exertional malaise.
  • The 203-participant trial showed no statistically significant efficacy improvements overall during 12 weeks of treatment, despite benefits in selected subgroups.
  • Safety and tolerability were comparable to placebo, with no serious treatment-emergent adverse events in the bezisterim group.
  • Additional data will be presented at the Long COVID International Conference in Nice, France, November 12-13, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090800PRIMZONEFULLFEED9872776) on November 09, 2026, and is solely responsible for the information contained therein.